At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 41 enrolled
Drug / intervention
MEDI0382 +1 moredrug
Likely dose
MEDI0382 50 μgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2a, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of MEDI0382 in Subjects With Type 2 Diabetes Mellitus and Renal Impairment
In Brief
A Phase 2 clinical trial evaluating MEDI0382 and Placebo for Type II Diabetes Mellitus and Renal Insufficiency. Completed, enrolled 41 participants across 7 sites in 2 countries.
Detailed Summary
A study to look at the effect MEDI0382 has on blood sugar in people with type 2 diabetes and kidney problems and also to check that MEDI0382 is well tolerated.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType II Diabetes Mellitus, Renal Insufficiency
CountriesGermany, United Kingdom
Collaborators--
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
First PostedJun 2018
Enrollment StartJun 2018
Primary CompletionFeb 2019
TodayJul 2026
First PostedJun 8, 2018
Enrollment StartJun 29, 2018
Primary CompletionFeb 4, 2019
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 8.1 years ago
Interventions
MEDI0382drug
Participants will receive subcutaneous MEDI0382 titrated from 50 μg upto 300 μg (50 μg once daily for 4 days, followed by 100 μg daily for 7 days, 200 μg daily for 7 days, and 300 μg daily for 14 days) for 32 days.
Placebodrug
Participants will receive SC placebo matched to MEDI0382 once daily for 32 days.